267 related articles for article (PubMed ID: 19273907)
1. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.
Han S; Liang CP; Westerterp M; Senokuchi T; Welch CL; Wang Q; Matsumoto M; Accili D; Tall AR
J Clin Invest; 2009 Apr; 119(4):1029-41. PubMed ID: 19273907
[TBL] [Abstract][Full Text] [Related]
2. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
Ai D; Chen C; Han S; Ganda A; Murphy AJ; Haeusler R; Thorp E; Accili D; Horton JD; Tall AR
J Clin Invest; 2012 Apr; 122(4):1262-70. PubMed ID: 22426206
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4.
Wang B; Shen Y; Zhai L; Xia X; Gu HM; Wang M; Zhao Y; Chang X; Alabi A; Xing S; Deng S; Liu B; Wang G; Qin S; Zhang DW
J Lipid Res; 2021; 62():100091. PubMed ID: 34118252
[TBL] [Abstract][Full Text] [Related]
4. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
5. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice.
Zhao Y; Su B; Jacobs RL; Kennedy B; Francis GA; Waddington E; Brosnan JT; Vance JE; Vance DE
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1349-55. PubMed ID: 19520976
[TBL] [Abstract][Full Text] [Related]
6. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
7. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.
Mulvihill EE; Assini JM; Lee JK; Allister EM; Sutherland BG; Koppes JB; Sawyez CG; Edwards JY; Telford DE; Charbonneau A; St-Pierre P; Marette A; Huff MW
Diabetes; 2011 May; 60(5):1446-57. PubMed ID: 21471511
[TBL] [Abstract][Full Text] [Related]
8. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
[TBL] [Abstract][Full Text] [Related]
9. Normal production rate of apolipoprotein B in LDL receptor-deficient mice.
Millar JS; Maugeais C; Fuki IV; Rader DJ
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):989-94. PubMed ID: 12067909
[TBL] [Abstract][Full Text] [Related]
10. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.
Mulvihill EE; Allister EM; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Markle JM; Hegele RA; Huff MW
Diabetes; 2009 Oct; 58(10):2198-210. PubMed ID: 19592617
[TBL] [Abstract][Full Text] [Related]
11. Obesity causes very low density lipoprotein clearance defects in low-density lipoprotein receptor-deficient mice.
Coenen KR; Gruen ML; Hasty AH
J Nutr Biochem; 2007 Nov; 18(11):727-35. PubMed ID: 17418556
[TBL] [Abstract][Full Text] [Related]
12. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
Fu T; Mukhopadhyay D; Davidson NO; Borensztajn J
J Biol Chem; 2004 Jul; 279(27):28662-9. PubMed ID: 15123680
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3α deficiency attenuates atherosclerosis and hepatic steatosis in high fat diet-fed low density lipoprotein receptor-deficient mice.
Banko NS; McAlpine CS; Venegas-Pino DE; Raja P; Shi Y; Khan MI; Werstuck GH
Am J Pathol; 2014 Dec; 184(12):3394-404. PubMed ID: 25451156
[TBL] [Abstract][Full Text] [Related]
14. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice.
Coenen KR; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E492-9. PubMed ID: 17566116
[TBL] [Abstract][Full Text] [Related]
15. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice.
Ai D; Baez JM; Jiang H; Conlon DM; Hernandez-Ono A; Frank-Kamenetsky M; Milstein S; Fitzgerald K; Murphy AJ; Woo CW; Strong A; Ginsberg HN; Tabas I; Rader DJ; Tall AR
J Clin Invest; 2012 May; 122(5):1677-87. PubMed ID: 22466652
[TBL] [Abstract][Full Text] [Related]
16. Alleviating VLDL overproduction is an important mechanism for Laminaria japonica polysaccharide to inhibit atherosclerosis in LDLr
Zha XQ; Zhang WN; Peng FH; Xue L; Liu J; Luo JP
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27928899
[TBL] [Abstract][Full Text] [Related]
17. PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins.
Lindén D; Alsterholm M; Wennbo H; Oscarsson J
J Lipid Res; 2001 Nov; 42(11):1831-40. PubMed ID: 11714852
[TBL] [Abstract][Full Text] [Related]
18. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice.
Vasandani C; Kafrouni AI; Caronna A; Bashmakov Y; Gotthardt M; Horton JD; Spady DK
J Lipid Res; 2002 May; 43(5):772-84. PubMed ID: 11971949
[TBL] [Abstract][Full Text] [Related]
20. Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.
Johnson LA; Altenburg MK; Walzem RL; Scanga LT; Maeda N
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1745-52. PubMed ID: 18617647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
